Selected Publications
1. Chiarle R, Gong JZ, Guasparri I, Pesci A, Cai H, Liu J, Simmons WJ, Dhall G, Howes J, Piva R, Inghirami G. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood. 2003;101(5):1919-1927
2. Maritano D, Sugrue ML, Tininini S, Dewilde S, Strobl B, Fu X, Murray-Tait V, Chiarle R, Poli V. The STAT3 isoforms alpha and beta have unique and specific functions. Nat Immunol. 2004;5(4):401-9
3. Chiarle R, Simmons WJ, Cai H, Dhall G, Zamo’ A, Raz R, Karras J, Levy DE , Inghirami G. Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target. Nat Medicine. 2005;11(6): 623-629
4. Ambrogio C, Voena C, Manazza AD, Piva R, Riera L, Barberis L, Costa C, Tarone G, Defilippi P, Hirsch E, Erba EB, Mohammed S, Jensen ON, Palestro G, Inghirami G, Chiarle R. p130Cas mediates the transforming properties of the anaplastic lymphoma kinase. Blood. 2005 Dec 1;106(12):3907-16.
5. Piva R*, Chiarle R*§, Manazza AD*, Taulli R, Simmons W, Ambrogio C, D'Escamard V, Pellegrino E, Ponzetto C, Palestro G, Inghirami G. Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas. Blood. 2006 Jan 15;107(2):689-97. PMCID: PMC1895619.
* These authors equally contributed to the work, § Corresponding Author
6. Voena C, Conte C, Ambrogio C, Boeri Erba E, Boccalatte F, Mohammed S, Jensen ON, Palestro G, Inghirami G, Chiarle R. The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration. Cancer Res. 2007 May 1;67(9):4278-86.
7. Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer. 2008 Jan;8(1):11-23.
8. Chiarle R, Martinengo C, Mastini C, Ambrogio C, D’Escamard V, Forni G, Inghirami G. Anaplastic Lymphoma Kinase is an effective oncoantigen for lymphoma vaccination. Nat Medicine. 2008 Jun;14(6):676-80
9. Ambrogio C, Voena C, Manazza AD, Martinengo C, Costa C, Kirchhausen T, Hirsch E, Inghirami G, Chiarle R. The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation. Cancer Res. 2008 Nov 1;68(21):8899-907. PMCID: PMC2596920.
10. Ambrogio C, Martinengo C, Voena C, Tondat F, Riera L, di Celle PF, Inghirami G, Chiarle R. NPM-ALK oncogenic tyrosine kinase controls T-cell identity by transcriptional regulation and epigenetic silencing in lymphoma cells. Cancer Res. 2009 Nov 15;69(22):8611-9. PMCID: PMC2784121.
11. Gostissa M, Alt FW, Chiarle R. Mechanisms that promote and suppress chromosomal translocations in lymphocytes. Annu. Rev. Immunol. 2011 Apr 23;29:319-50.
12. Chiarle R, Zhang Y, Frock RL, Lewis SM, Molinie B, Ho Y, Myers DR, Choi VW, Compagno M, Malkin DJ, Neuberg D, Monti S, Giallourakis CC, Gostissa M, and Alt FW. Genome-Wide Translocation Sequencing Reveals Mechanisms of Chromosome Breaks and Rearrangements in B Cells.Cell 2011 Sep 30;147(1):107-19.
13. Duan S, Cermak L, Pagan J, Rossi M, Martinengo C, Francia di Celle P, Chapuy B, Shipp M, Chiarle R*, and Pagano M*. FBXO11 targets BCL6 for degradation and is inactivated in Diffuse Large B-Cell Lymphomas. Nature 2012, 481(7379):90-3.
* Corresponding Authors
14. Chiarle R. Translocations in normal B cells and cancers: insights from new technical approaches. Advances Immunol 2013, 117:39-71
15. Crosetto N, Mitra A, Silva MJ, Bienko M, Dojer N, Wang Q, Karaca E, Chiarle R, Skrzypczak M, Ginalski K, Pasero P, Rowicka M, Dikic I. Nucleotide-resolution DNA double-strand break mapping by next-generation sequencing Nat Methods. 2013 Apr;10(4):361-5.
16. Semrau S, Crosetto N, Bienko M, Boni M, Bernasconi P, Chiarle R*, van Oudenaarden A*. FuseFISH: Robust Detection of Transcribed Gene Fusions in Single Cells. Cell Reports 2014 Jan 16;6(1):18-23.
* Corresponding Authors